Clinical research

An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents

EuroIntervention 2014;10:224-230 published online ahead of print October 2013. DOI: 10.4244/EIJV10I2A36

Katharina M. Katsaros
Katharina M. Katsaros1,2, MD; Stefan P. Kastl1,2, MD; Konstantin A. Krychtiuk1,2, MD; Randolph Hutter3, MD; Gerlinde Zorn1, BSc; Gerald Maurer1, MD; Kurt Huber4, MD; Johann Wojta1,2, PhD; Günter Christ5, MD; Walter S. Speidl1*, MD
1. Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; 2. Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria; 3. The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New

Aims: Drug-eluting stents (DES) reduce late lumen loss compared to bare metal stents but were not able to eradicate in-stent restenosis (ISR) fully. Vascular endothelial growth factor (VE

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

coronary interventiondrug-eluting stentsrestenosisvegf
Read next article
Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)

Latest news